• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biotechnology Progress >Glycosylation of monoclonal antibody products: Current status and future prospects
【24h】

Glycosylation of monoclonal antibody products: Current status and future prospects

机译：单克隆抗体产品的糖基化：现状和未来展望

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Protein based therapeutics have started to dominate the pharmaceutical landscape primarily due to the high efficacy that they have demonstrated against complex diseases. Despite the significant success, issues with regards to safety, efficacy and quality of biotherapeutics have been a point of considerable debate and concern among the various stakeholders. The correlation between the glycoform profile and the safety and efficacy of a drug, in particular, has garnered significant attention of researchers worldwide. An escalated emphasis is presently given to develop an understanding of how the various process parameters as well molecular biology considerations contribute to glycan heterogeneity. This paper aims to review the major developments that have occurred in this area over the last decade. The impact of the various process parameters on glycan expression, methods for obtaining a pre-determined glycan levels/profiles of a protein therapeutic and developments in the area of real-time glycan monitoring and control are discussed. (c) 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1091-1102, 2016
机译：基于蛋白质的疗法已开始在药物领域占据主导地位，这主要是由于它们已证明对复杂疾病的高功效。尽管取得了巨大的成功，但有关生物治疗的安全性，功效和质量的问题仍是各利益相关者之间颇有争议和关注的问题。特别地，糖型概况与药物的安全性和功效之间的相关性已引起全世界研究人员的极大关注。目前，人们逐渐加重对各种工艺参数以及分子生物学因素如何影响聚糖异质性的理解。本文旨在回顾过去十年中该领域的主要发展。讨论了各种工艺参数对聚糖表达的影响，获得蛋白质治疗剂的预定聚糖水平/特征的方法以及实时聚糖监测和控制领域的发展。 （c）2016美国化学工程师学会生物技术学会。 Prog。，32：1091-1102，2016

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号